Showing 8 of 8 recruiting trials for “familial-papillary-or-follicular-thyroid-carcinoma”
Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid Cancer
A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma
Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)
👨⚕️ Ramaprasad Srinivasan, M.D., National Cancer Institute (NCI)📍 1 site📅 Started Apr 2024View details ↗
Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer
👨⚕️ Yansong Lin, Ph D, Peking Union Medical College Hospital📍 1 site📅 Started Nov 2023View details ↗
Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
RecruitingNCT05994365 ↗
Study of Anlotinib Hydrochloride Capsules in the Treatment of Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →